CARISMA Therapeutics Inc (CARM)
2.27
+0.03
(+1.34%)
USD |
NASDAQ |
Mar 28, 16:00
2.26
-0.01
(-0.44%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 91.61M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -23.83% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 5.740 |
Price to Book Value | 1.979 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma’s proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. |
URL | https://www.carismatx.com |
Investor Relations URL | https://ir.carismatx.com/ |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Apr. 03, 2024 (est.) |
Last Earnings Release | Nov. 09, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma’s proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. |
URL | https://www.carismatx.com |
Investor Relations URL | https://ir.carismatx.com/ |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Apr. 03, 2024 (est.) |
Last Earnings Release | Nov. 09, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |